Literature DB >> 1656164

The causes of death in patients with human immunodeficiency virus infection: a clinical and pathologic study with emphasis on the role of pulmonary diseases.

R McKenzie1, W D Travis, S A Dolan, S Pittaluga, I M Feuerstein, J Shelhamer, R Yarchoan, H Masur.   

Abstract

The clinical records and autopsy data of 75 patients dying with AIDS were reviewed to determine the frequency of individual diseases diagnosed premortem and postmortem, the significance of pulmonary processes found in the lungs at autopsy, and the clinical and pathologic causes of death. Cytomegalovirus (CMV) infection was identified histologically either premortem or postmortem in 81% of patients. The lungs and adrenal glands were infected most commonly. Only one-half of CMV infections were recognized premortem. Pneumocystis pneumonia and Kaposi sarcoma occurred in 68% and 59% of patients, respectively, but were not unsuspected premortem in any patient. Visceral involvement with Kaposi sarcoma, however, was frequently recognized only at autopsy. While disseminated M. avium-intracellulare infection was common (31% of patients), histologically documented pulmonary disease was uncommon (3% of patients). Cryptococcal infection, diagnosed in 10 patients, was confined to the central nervous system in only 1 patient. Toxoplasma, in contrast, infected the brain of only 6 patients. All 75 patients had one or more disease processes identified in their lungs or pleurae at autopsy. These processes included opportunistic infections in 76% of patients, neoplasms in 37% (Kaposi sarcoma in 36% and lymphoma in 3%), and other processes in 60%. The most prevalent pathogen, CMV was found in pulmonary tissue from 44 patients and caused significant disease in 21 patients. Five patients died due to CMV pneumonia. Pneumocystis carinii was found at autopsy in 24 patients. In spite of treatment, pneumocystis pneumonia was fatal in 11 patients. One patient died with concomitant CMV and pneumocystis pneumonia. Kaposi sarcoma, identified in the lungs of 23 patients, led to death in 5 patients via upper airway obstruction, hemorrhage, or parenchymal destruction. Other fatal pulmonary processes included bacterial pneumonia in 9 patients, idiopathic diffuse alveolar damage in 5, cryptococcosis in 2, and pulmonary hemorrhage in 1. Specific clinical criteria were used to determine the cause of death due to organ system failure. Fifty-one percent of patients died due to respiratory failure; 16% from neurologic disease; 17% from hypotension that was not caused by respiratory, neurologic, or cardiac disease; and 3% from cardiac dysfunction. Thirteen percent of deaths did not meet the clinical criteria defining these 4 categories. This clinical assessment was combined with autopsy data to identify specific diseases as causes of death.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Year:  1991        PMID: 1656164     DOI: 10.1097/00005792-199109000-00004

Source DB:  PubMed          Journal:  Medicine (Baltimore)        ISSN: 0025-7974            Impact factor:   1.889


  25 in total

1.  Phosphorylation of beta-D-ribosylbenzimidazoles is not required for activity against human cytomegalovirus.

Authors:  Paula M Krosky; Katherine Z Borysko; M Reza Nassiri; Rodrigo V Devivar; Roger G Ptak; Michelle G Davis; Karen K Biron; Leroy B Townsend; John C Drach
Journal:  Antimicrob Agents Chemother       Date:  2002-02       Impact factor: 5.191

Review 2.  Management of patients with HIV in the intensive care unit.

Authors:  Henry Masur
Journal:  Proc Am Thorac Soc       Date:  2006

3.  Pneumonitis in human cytomegalovirus infection.

Authors:  Erik Langhoff; Robert E Siegel
Journal:  Curr Infect Dis Rep       Date:  2006-05       Impact factor: 3.725

4.  Bilateral Chest X-Ray Shadowing and Bilateral leg lesions - A case of Pulmonary Kaposi Sarcoma.

Authors:  M Khattak
Journal:  Webmedcentral       Date:  2016-02-17

5.  Antiproliferative effect of retinoid compounds on Kaposi's sarcoma cells.

Authors:  J Corbeil; E Rapaport; D D Richman; D J Looney
Journal:  J Clin Invest       Date:  1994-05       Impact factor: 14.808

6.  Resistance of human cytomegalovirus to the benzimidazole L-ribonucleoside maribavir maps to UL27.

Authors:  Gloria Komazin; Roger G Ptak; Brian T Emmer; Leroy B Townsend; John C Drach
Journal:  J Virol       Date:  2003-11       Impact factor: 5.103

7.  Foscarnet penetrates the blood-brain barrier: rationale for therapy of cytomegalovirus encephalitis.

Authors:  U R Hengge; N H Brockmeyer; R Malessa; U Ravens; M Goos
Journal:  Antimicrob Agents Chemother       Date:  1993-05       Impact factor: 5.191

8.  Selective cytotoxicity of ricin A chain immunotoxins towards murine cytomegalovirus-infected cells.

Authors:  B B Barnett; D F Smee; S M Malek; R W Sidwell
Journal:  Antimicrob Agents Chemother       Date:  1996-02       Impact factor: 5.191

9.  Comparative analysis of intrathecal antibody synthesis and DNA amplification for the diagnosis of cytomegalovirus infection of the central nervous system in AIDS patients.

Authors:  T Weber; R Beck; E Stark; J Gerhards; K Korn; J Haas; W Lüer; G Jahn
Journal:  J Neurol       Date:  1994-06       Impact factor: 4.849

10.  Post-mortem histological pulmonary analysis in patients with HIV/AIDS.

Authors:  Alexandre de Matos Soeiro; André L D Hovnanian; Edwin Roger Parra; Mauro Canzian; Vera Luiza Capelozzi
Journal:  Clinics (Sao Paulo)       Date:  2008-08       Impact factor: 2.365

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.